Bicalutamide and third-generation aromatase inhibitors in testotoxicosis

Pediatrics

Volumn 126, Issue 3, 2010, Pages

  Lenz, Anne M ^a   Shulman, Dorothy ^a   Eugster, Erica A ^b   Rahhal, Samar ^c   Fuqua, John S ^b   Pescovitz, Ora H ^d   Lewis, Katherine A ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Peyton Manning Children's Hospital   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Age determination by skeleton; Aromatase inhibitors; Bicalutamide; Gonadal disorders; Precocious puberty

Indexed keywords

ANASTROZOLE; BICALUTAMIDE; FOLLITROPIN; GONADORELIN; LETROZOLE; LEUPRORELIN; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; SPIRONOLACTONE; TESTOLACTONE; TESTOSTERONE; ANILIDE; ANTIANDROGEN; AROMATASE INHIBITOR; NITRILE; TOLUENESULFONIC ACID DERIVATIVE; TRIAZOLE DERIVATIVE;

ARTICLE; BONE AGE; BONE GROWTH; CASE REPORT; CHILD; DRUG TOLERABILITY; FATHER; FOLLITROPIN BLOOD LEVEL; GENITAL SYSTEM DISEASE; GONADORELIN TEST; GROWTH RATE; HOT FLUSH; HUMAN; LONG TERM CARE; LUTEINIZING HORMONE BLOOD LEVEL; MALE; PATIENT COMPLIANCE; PENIS; PRECOCIOUS PUBERTY; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; TALL STATURE; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL; TESTOTOXICOSIS; TREATMENT DURATION; VIRILIZATION; BLOOD; PUBERTY, PRECOCIOUS;

ANDROGEN ANTAGONISTS; ANILIDES; AROMATASE INHIBITORS; CHILD, PRESCHOOL; HUMANS; MALE; NITRILES; PUBERTY, PRECOCIOUS; TESTOSTERONE; TOSYL COMPOUNDS; TRIAZOLES;

EID: 77956279347     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-0596     Document Type: Article

References (34)

1. Shenker A, Laue L, Kosugi S, Merendino JJ Jr, Minegishi T, Cutler GB Jr. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature. 1993;365(6447):652-654
2. Kawate N, Kletter GB, Wilson BE, Netzloff ML, Menon KMJ. Identification of constitutively activating mutation of the luteinising hormone receptor in a family with male limited gonadotropin independent precocious puberty (testotoxicosis). J Med Genet. 1995;32(7):553-554
3. Schedewie HK, Reiter EO, Beitins IZ, et al. Testicular Leydig cell hyperplasia as a cause of familial sexual precocity. J Clin Endocrinol Metab. 1981;52(2):271-278
4. Rosenthal SM, Grumbach MM, Kaplan SL. Gonadotropin independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases. J Clin Endocrinol Metab. 1983;57(3):571-579
5. Egli CA, Rosenthal SM, Grumbach MM, Montalvo JM, Gondos B. Pituitary gonadotropinin-dependent male-limited autosomal dominant sexual precocity in nine generations: familial testotoxicosis. J Pediatr. 1985;106(1):33-40
6. Reiter EO, Brown RS, Longcope C, Beitins IZ. Male-limited familial precocious puberty in three generations: apparent Leydig-cell autonomy and elevated glycoprotein hormone alpha subunit. N Engl J Med. 1984;311(8):515-519 (Pubitemid 14059354)
7. Reiter EO, Narjavaara E. Testotoxicosis: current viewpoint. Pediatr Endocrinol Rev. 2005;3(2):77-86
8. Piersma D, Verhoef-Post M, Berns EM, Themmen AP. LH receptor gene mutations and polymorphisms: an overview. Mol Cell Endocrinol. 2007;260:-262:282-286
9. Latronico AC, Segaloff DL. Naturally occurring mutations of the luteinizing-hormone receptor: lessons learned about reproductive physiology and G protein-coupled receptors. Am J Hum Genet. 1999;65(4):949-958
10. Clapham DE. Signal transduction: why testes are cool. Nature. 1994;371(6493):109-110
11. Bertelloni S, Baroncelli GI, Lala R, et al. Long-term outcome of male-limited gonadotropin-independent precocious puberty. Horm Res. 1997;48(5):235-239
12. Kreher NC, Pescovitz OH, Delameter P, Tiulpakov A, Hochberg Z. Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. J Pediatr. 2006;149(3):416-420 (Pubitemid 44308423)
13. Rajfer J, Sikka S, Rivera F, Handelsman DJ. Mechanism of inhibition of human testicular steroidogenesis by oral ketoconazole. J Clin Endocrinol Metab. 1986;63(5):1193-1198
14. Holland FJ, Fishman L, Bailey JD, Fazekas AT. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. N Engl J Med. 1985;312(16):1023-1028 (Pubitemid 15114290)
15. Corvol P, Michaund A, Menard J, Freifeld M, Mahoudeau J. Antiandrogenic effect of spironolactones: mechanism of action. Endocrinology. 1975;97(1):52-58
16. Soriano-Guillén L, Lahlou N, Chauvet G, Roger M, Chaussain JL, Carel JC. Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty. J Clin Endocrinol Metab. 2005;90(1):147-151
17. Babovic-Vuksanovic D, Donaldson MD, Gibson NA, Wallace AM. Hazards of ketoconazole therapy in testotoxicosis. Acta Paediatr. 1994;83(9):994-997
18. Almeida MQ, Brito VN, Lins TS, et al. Long-term treatment of familial male-limited precocious puberty (testotoxicosis) with cyproterone acetate or ketoconazole. Clin Endocrinol (Oxf). 2008;69(1):93-98
19. Best TR, Jenkins JK, Murphy FY, Nicks SA, Bussell KL, Vesely DL. Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy. Am J Med. 1987;82(3 Spec No.):676-680
20. Laue L, Kenigsberg D, Pescovitz OH, et al. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med. 1989;320(8):496-5022492636
21. Laue L, Jones J, Barnes KM, Cutler GB Jr. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin. J Clin Endocrinol Metab. 1993;76(1):151-155 (Pubitemid 23027570)
22. Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB Jr. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab. 1999;84(1):175-178
23. Furr BJ. The development of Casodex (bicalutamide): preclinical studies. Eur Urol. 1996;29(suppl 2):83-95
24. Morishima A, Grumbach M, Simpson E, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80(12):3689-3698
25. Dunkel L. Use of aromatase inhibitors to increase final height. Mol Cell Endcrinol. 2006;254-255:207-216 (Pubitemid 44041744)
26. Plourde PV, Reiter EO, Jou HC, et al; Members of the Astra-Zeneca Gynecomastia Study. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89(9):4428-4433
27. Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab. 2005;90(12):6396-6402
28. Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler GB Jr. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2000;85(3):1114-1120
29. Geisler J, Lonning PE. Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005;11(8):2809-2821 (Pubitemid 40525179)
30. Eyssette-Guerreau S, Pinto G, Sultan A, Le Merrer M, Sultan C, Polak M. Effectiveness of anastrozole and cyproterone acetate in two brothers with familial male precocious puberty. J Pediatr Endocrinol Metab. 2008;21(10):995-1002
31. Mauras N, O'Brien KO, Klein KO, Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab. 2000;85(7):2370-2377
32. Hero M, Mäkitie O, Kröger H, Nousiainen, Toiviainen-Salo S, Dunkel L. Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. Hormone Res. 2009;71(5):290-297
33. Hayes FJ, Seminara SB, Decruz S, Boepple PA, Crowley WF Jr. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback. J Clin Endocrinol Metab. 2000;85(9):3027-3035
34. Shaw ND, Histed SN, Srouji SS, et al. Estrogen negative feedback on gonadotropin secretion: evidence for a direct pituitary effect in women. J Clin Endocrinol Metab. 2010;95(4):1955-1961